IL280025B2 - JAK inhibitor compound xinafoate salt - Google Patents
JAK inhibitor compound xinafoate saltInfo
- Publication number
- IL280025B2 IL280025B2 IL280025A IL28002521A IL280025B2 IL 280025 B2 IL280025 B2 IL 280025B2 IL 280025 A IL280025 A IL 280025A IL 28002521 A IL28002521 A IL 28002521A IL 280025 B2 IL280025 B2 IL 280025B2
- Authority
- IL
- Israel
- Prior art keywords
- asthma
- bronchitis
- fluoro
- xinafoate salt
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699955P | 2018-07-18 | 2018-07-18 | |
| US201962866013P | 2019-06-25 | 2019-06-25 | |
| PCT/EP2019/069252 WO2020016302A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL280025A IL280025A (en) | 2021-03-01 |
| IL280025B1 IL280025B1 (en) | 2024-10-01 |
| IL280025B2 true IL280025B2 (en) | 2025-02-01 |
Family
ID=67396927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280025A IL280025B2 (en) | 2018-07-18 | 2019-07-17 | JAK inhibitor compound xinafoate salt |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149029B2 (https=) |
| EP (1) | EP3823964A1 (https=) |
| JP (2) | JP7422732B2 (https=) |
| KR (1) | KR102849420B1 (https=) |
| CN (2) | CN118580223A (https=) |
| AU (1) | AU2019304014B2 (https=) |
| BR (1) | BR112021000467A2 (https=) |
| CA (1) | CA3105585A1 (https=) |
| IL (1) | IL280025B2 (https=) |
| MA (1) | MA53162A (https=) |
| MX (1) | MX2021000611A (https=) |
| MY (1) | MY209356A (https=) |
| SG (1) | SG11202100240RA (https=) |
| WO (1) | WO2020016302A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| MX2013003019A (es) * | 2010-09-15 | 2013-05-28 | Hoffmann La Roche | Compuestos de azabenzotiazol, composiciones y metodos de uso. |
| AU2014342338B2 (en) * | 2013-11-01 | 2016-12-01 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| PL3189045T3 (pl) | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Nowe sole nilotynibu i jego polimorfy |
| BR112018005833B1 (pt) * | 2015-09-25 | 2023-10-10 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto |
| KR102585048B1 (ko) | 2017-01-17 | 2023-10-05 | 아스트라제네카 아베 | Jak1 선택적 억제제 |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
-
2019
- 2019-07-17 SG SG11202100240RA patent/SG11202100240RA/en unknown
- 2019-07-17 EP EP19742558.0A patent/EP3823964A1/en active Pending
- 2019-07-17 AU AU2019304014A patent/AU2019304014B2/en active Active
- 2019-07-17 CN CN202410624343.9A patent/CN118580223A/zh active Pending
- 2019-07-17 MA MA053162A patent/MA53162A/fr unknown
- 2019-07-17 MY MYPI2021000231A patent/MY209356A/en unknown
- 2019-07-17 US US16/513,781 patent/US11149029B2/en active Active
- 2019-07-17 JP JP2021502626A patent/JP7422732B2/ja active Active
- 2019-07-17 CN CN201980047093.4A patent/CN112424187B/zh active Active
- 2019-07-17 KR KR1020217001860A patent/KR102849420B1/ko active Active
- 2019-07-17 MX MX2021000611A patent/MX2021000611A/es unknown
- 2019-07-17 WO PCT/EP2019/069252 patent/WO2020016302A1/en not_active Ceased
- 2019-07-17 BR BR112021000467-0A patent/BR112021000467A2/pt unknown
- 2019-07-17 CA CA3105585A patent/CA3105585A1/en active Pending
- 2019-07-17 IL IL280025A patent/IL280025B2/en unknown
-
2023
- 2023-10-02 JP JP2023171327A patent/JP7644190B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019304014B2 (en) | 2022-08-18 |
| IL280025B1 (en) | 2024-10-01 |
| KR102849420B1 (ko) | 2025-08-25 |
| WO2020016302A1 (en) | 2020-01-23 |
| BR112021000467A2 (pt) | 2021-04-06 |
| WO2020016302A8 (en) | 2020-11-12 |
| JP2024001109A (ja) | 2024-01-09 |
| MA53162A (fr) | 2021-05-26 |
| CN112424187B (zh) | 2024-06-21 |
| IL280025A (en) | 2021-03-01 |
| AU2019304014A1 (en) | 2021-03-04 |
| SG11202100240RA (en) | 2021-02-25 |
| MY209356A (en) | 2025-07-03 |
| MX2021000611A (es) | 2021-04-13 |
| EP3823964A1 (en) | 2021-05-26 |
| CN112424187A (zh) | 2021-02-26 |
| US11149029B2 (en) | 2021-10-19 |
| KR20210033474A (ko) | 2021-03-26 |
| CA3105585A1 (en) | 2020-01-23 |
| CN118580223A (zh) | 2024-09-03 |
| US20200062737A1 (en) | 2020-02-27 |
| JP7422732B2 (ja) | 2024-01-26 |
| JP7644190B2 (ja) | 2025-03-11 |
| JP2021530526A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7644190B2 (ja) | Ｊａｋ阻害化合物のキシナホ酸塩 | |
| US9868739B2 (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| CN104860941B (zh) | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 | |
| JP7105781B2 (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| US9879008B2 (en) | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | |
| CA3143490C (en) | Disubstituted pyrazole compounds as ketohexokinase inhibitors | |
| US20100234599A1 (en) | Method for preparing acid addition salts of polyacidic basic compounds | |
| US20230303534A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| WO2018170199A1 (en) | Forms and compositions of a mk2 inhibitor | |
| KR20250049276A (ko) | 오비세트라피브(obicetrapib)의 염 및 그의 제조 방법 및 그의 중간체 | |
| EA044028B1 (ru) | Ксинафоатная соль соединения, ингибирующего jak | |
| CN121605107A (zh) | 2-[(3r)-2-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4[4-(氧杂环丁烷-3-基)哌嗪-1-基]-戊-2-烯腈及其溶剂化物形式的制备方法 | |
| WO2025207649A1 (en) | Solid state forms of an akt1 inhibitor and salts thereof | |
| CN119490507A (zh) | 一种新型激酶抑制剂 | |
| HK40072166A (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| HK40062437A (en) | Disubstituted pyrazole compounds as ketohexokinase inhbitors | |
| HK1185617B (en) | Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| HK1185617A (en) | Succinate salt of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |